NATICK, Mass., Dec. 8, 2025 /PRNewswire/ -- Pillar Biosciences announced today an expansion of its existing laboratory access program with AstraZeneca for NGS-based kitted liquid biopsy tumor profiling to include China. This expanded collaboration aims to deliver rapid, cost-effective,...
Hence then, the article about pillar biosciences and astrazeneca expand liquid biopsy access partnership to china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China )
Also on site :
- China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
- The shadow Russia casts over Europe has forced it to face the truth: the risk of war is once again real
- Goldman Sachs expects layoffs to keep rising—and says investors are punishing the stocks of companies that slash staff